Compare Natera Inc. Common Stock (NTRA) vs State Street PDR S&P Retail ETF (XRT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Natera Inc. Common Stock vs State Street PDR S&P Retail ETF — how do they compare? Natera Inc. Common Stock trades at $394.6 (market cap $57.03B), while State Street PDR S&P Retail ETF trades at $84.83 (market cap $374.32M). The key difference: Natera Inc. Common Stock is far larger — about 152.4× State Street PDR S&P Retail ETF's market cap, and Natera Inc. Common Stock is trading nearer its 52-week high, State Street PDR S&P Retail ETF nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Natera Inc. Common Stock for 0 Days and State Street PDR S&P Retail ETF for 45 Days on average.
| NTRA | XRT | |
|---|---|---|
Market Cap | $57.03B | $374.32M |
Volume | 1,131,157 | 3,523,512 |
Sector | Health | Broad Market / Factor |
52-Week High | $425.64 | $92.35 |
52-Week Low | $179.42 | $77.28 |
Typical Hold Time | 0 Days | 45 Days |
Enterprise Value | $56.18B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
NTRA trades at $395.66, down 0.53% today but remains near recent highs. The stock shows mixed technical signals with neutral momentum indicators. Fundamentally, the company demonstrates strong revenue growth ($2.31B in 2025, projected $2.7B in 2026) but continues to operate at a net loss (-$208M in 2025). Recent positive developments include FDA Breakthrough Device designation for its multi-cancer detection assay and regulatory approval in Japan for Signatera.
NTRA presents a growth story with significant analyst support (89% buy ratings) but carries execution risks. The stock trades at premium valuations (P/S 20.48) while still unprofitable. Key catalysts include clinical trial progress and international expansion, though investors face risks from ongoing losses and competitive pressures in precision medicine.
XRT (SPDR S&P Retail ETF) trades at $84.33, showing minimal daily movement with a 0.21% gain. Technical indicators present a mixed picture with bearish moving averages but neutral overall signals. The ETF faces headwinds from higher interest rates and inflation impacting consumer sentiment, with recent retail sales showing volatility. XRT has underperformed the broader market year-to-date, reflecting sector-specific challenges in the retail landscape.
The retail sector outlook remains cautious amid macroeconomic pressures, though potential trade resolution benefits and holiday sales projections offer some optimism. Key risks include consumer spending sensitivity to economic conditions and competitive pressures. Analyst sentiment leans neutral with expectations of continued relative underperformance versus broader market indices into 2027.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Natera Inc. Common Stock
Natera, Inc. develops and provides cell-free DNA-based genetic testing across women's health, oncology, organ health, and rare disease, with flagship products including Panorama for noninvasive prenatal screening and Signatera for cancer recurrence monitoring.
Read more on NTRA →About State Street PDR S&P Retail ETF
XRT is an equal-weighted ETF that tracks the U.S. retail sector. It provides diversified exposure to apparel, automotive, and online retailers, including well-known names like Amazon, Target, and Costco.
Read more on XRT →
